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Collagen cross-linking in the treatment 
of pellucid marginal degeneration
Ziad Hassan, Gabor Nemeth1, Laszlo Modis1, Eszter 
Szalai1, Andras Berta1
Pellucid	marginal	 degeneration	 (PMD)	 is	 an	 uncommon	 cause	
of	 inferior	 peripheral	 corneal	 thinning	 disorder,	 characterized	
by irregular	astigmatism.	We	analyzed	a	 case	of	bilateral	PMD	
patient	and	 treated	one	eye	with	corneal	collagen	cross-linking	
(CXL)	 therapy.	 Corneal	 topography	 was	 characteristic	 for	
PMD.	 Visual	 acuity,	 slitlamp	 examinations,	 tonometry,	 and	
corneal	 thickness	 were	 observed.	 Simulated	 keratometric	 and	
topographic	index	values	were	detected	with	corneal	topography.	
Uncorrected,	LogMAR	visual	acuity	has	improved	from	+0.8	to	
+0.55 during	the	6	months	and	+0.3	during	the	8	months	follow-
up	 after	 CXL.	 Pachymetry	 values	 and	 intraocular	 pressure	
showed	no	changes.	Keratometric	values	and	topografic	indexes	
disclosed	no	progression	of	 the	disease.	CXL	may	postpone	or	
eliminate	the	need	of	corneal	transplantation	in	cases	with	PMD.
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Pellucid	marginal	 degeneration	 (PMD)	 of	 the	 cornea	 is	 a	
progressive,	rare,	and	uncommon	noninflammatory	corneal	
disorder	 characterized	 by	 the	 thinning	 in	 the	 peripheral	
portion	of	the	inferior	cornea	with	marked	steepening	just	
superior	to	the	thinned	zone.[1,2]	It	occurs	in	both	men	and	
women	 and	 can	 be	 differentiated	 from	 other	 peripheral	
corneal	 thinning	 disorders	 such	 as	 keratoconus	 and	
keratoglobus	by	its	characteristics	that	this	thinning	occurs	
1–3	mm	from	the	limbus	in	the	4–8	o’clock	position.[3]	It	is	
differentiated	from	peripheral	corneal	disorders	associated	
with	inflammation	such	as	Terrien’s	marginal	degeneration	
and	Mooren’s	 ulcer	 by	 the	 absence	 of	 vascularisation.	
Although	histopathologically	 it	 is	 considered	 a	 variant	 of	
keratoconus,	it	differs	in	that	the	marked	corneal	steepening	
occurs	more	inferiorly.[1]
Corneal	cross-linking	was	introduced	by	Wollensak	et al.	in	
2003	for	the	treatment	of	progressive	keratoconus	and	related	
disorders	increasing	the	biomechanical	strength	of	the	cornea	
by	about	300%.[4]
Here	we	present	one	 case	 showing	 the	 features	of	PMD	
both	clinically	and	topographically	treated	by	collagen	cross-
linking	 (CXL).	 It	was	 clinically	 typical	 bilateral	 PMD	with	
a	 characteristic	pattern	of	 irregular	 astigmatism	on	 corneal	
topography,	with	chief	complaints	of	progressive	dimness	of	
vision	caused	by	irregular	astigmatism.	The	CXL	treatment	can	
stop	PMD	progression	and	produce	better	quality	of	vision.
Case Report
We	analyzed	a	case	of	advanced	bilateral	PMD	patient	and	
treated	 one	 eye	with	 corneal	CXL.	A	 55-year-old	male	 is	
presented,	 complaining	 of	 progressive	 dimness	 of	 vision	
in	 both	 eyes	with	 decreased	 vision	 started	 1	 year	 before	
examinations	at	our	clinic,	but	the	visual	loss	was	larger	in	
the	right	eye.	There	was	no	history	of	excessive	eye	rubbing,	
trauma,	 contact	 lens	wear,	 or	 episodic	 redness	 of	 the	 eye.	
There	was	no	familiar	history.	Earlier,	he	was	diagnosed	with	
glaucoma	simplex	 treated	with	 timolol	0.5%.	His	right	eye	
was	pseudophakic,	and	his	left	eye	had	posterior	subcapsular	
cataract.	He	had	high	blood	pressure	 and	 type	 II	diabetes	
mellitus	was	 treated	 for	 around	9	 years.	 The	patient	 tried	
rigid	gas-permeable	 contact	 lenses	 but	 could	never	 get	 an	
acceptable	fit.	Visual	 acuity,	 slitlamp	 examination,	 corneal	
thickness	map	measurement	 (Pentacam	HR,	Oculus),	 and	
tonometry	were	carried	out,	and	simulated	keratometric	(SK1,	
SK2)	and	topographic	index	values	were	detected	with	corneal	
topograph	(Tomey	TMS4).
Ophthalmic	 examination	 revealed	his	 best-uncorrected	
visual	acuity,	a	value	of	+0.8	 in	 the	 right	eye	and	+0.1	 in	 the	
left	eye	observed	with	a	logarithmic	scale	(LogMAR).	Slitlamp	
examination	of	the	cornea	showed	inferior	peripheral	corneal-
thinning	without	iron	lines,	vascularization,	or	lipid	deposition	
[Fig.	1].	The	lesion	was	nonulcerative	and	inflammatory,	and	
implied	the	protrusion	of	the	cornea.	Between	the	thinned	area	
and	 the	 limbus,	 the	corneal	 thickness	was	normal.	However,	
the	left	eye	showed	a	clear	band	of	peripheral	thinning	about	
1–2	mm	wide,	with	anterior	protrusion	of	the	cornea	just	above	
the	 thinned	area.	A	2.0-mm	zone	of	normal-thickness	 cornea	
was	seen	between	the	thinned	area	and	the	limbus.	Scheimpflug	
image	(Oculus	Pentacam	HR)	of	the	anterior	segment	of	the	right	
eye	shows	irregular	shaped	central	corneal	region	[Fig.	2a	and	b].
Both	 anterior	 chambers	were	 4.11	mm	deep.	 Corneal	
thickness	measured	by	ultrasonic	pachymeter	of	the	right	eye	
were	502	μm	centrally	 and	520	μm	peripherally;	 in	 the	 left	
eye,	 the	readings	were	540	μm	centrally,	and	520	μm	at	 the	
periphery.	The	intraocular	pressure	measured	by	noncontact	
tonometry	was	in	normal	range	in	both	eyes.
Corneal	topography	was	characteristic	for	PMD.	The	vertical	
axis	images	showed	significant	central	irregular	against-the-
rule	astigmatism,	marked	peripheral	thinning	within	2.0	mm	
of	the	limbus,	and	more	normal	corneal	thickness	inferior	to	
the	band	of	 thinning.	Topograph	 sagittal	 curvature	map	on	
the	 right	 eye	 showed	vertical	flatting	and	 irregular	 inferior	
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corneal	 astigmatism.	The	horizontal	 axis	had	more	normal	
corneal	 contour	 and	 thickness.	Keratometric	 readings	were	
53.98D/36.04D	in	the	right	eye.	In	both	eyes,	there	was	a	bow-
tie-shaped	corneal	astigmatism	with	a	value	of	17.96D	in	the	
right	eye	[Fig.	3].	This	clinical	picture	was	consistent	with	a	
diagnosis	of	PMD	of	both	eyes.
CXL	was	performed	on	the	right	eye	using	InPro	CCL-Lix	
device	 (Norderstadt,	Germany).	During	 treatment,	 8	mm	
of	 the	 central	 corneal	 epithelium	was	 removed	 and	 0.1%	
riboflavin	solution	(with	20%	dextrane)	was	instilled	on	the	
surface	of	the	cornea	with	eccentric	method	of	Spadea[5]	and	
was	repeated	every	2	minutes	thereafter.	In	the	meantime,	
UV-A	irradiation	was	performed	with	an	emission	at	370	nm,	
with	radiant	energy	of	3	mW/cm2,	focusing	distance	of	60	mm,	
and	lasted	for	30	minutes.	The	postoperative	treatment	was	
antiobiotic	 eye	drops	 for	 5	days	 (tobramycin)	 and	 steroid	
eyedrops	(fluorometholone)	and	artificial	 tear	drops	for	at	
least	1	month.	We	did	not	use	contact	lens	postoperatively.	
There	 was	 no	 corneal	 edema	 or	 endothelial	 damage	
postoperatively.
The	 follow-up	 period	was	 8	months. Visual	 acuity,	
simulated	keratometric	indexes,	and	corneal	thickness	values	
were	detected	during	the	postoperative	period.	Uncorrected	
visual	acuity	has	increased	from	+0.8	to	+0.55;	best-corrected	
visual	acuity	was	+0.25	with	a	correction	of	spherical	equivalent	
of	-4.0	D	8	months	after	CXL	treatment.	After	CXL	treatment,	
SK1	decreased	to	50.48	D	and	SK2	to	33.97	D	[Fig.	4].	Pre-	and	
postoperative	 corneal	 back	 surface	 Scheimpflug	 pictures	
(Pentacam	HR)	do	not	show	difference	[Fig.	5].
Pachymetry	map	showed	minimal	 increase	 in	peripheral	
corneal	 thickness	 (from	520	μm	preoperatively	 to	 528	μm	
postoperatively)	 8	months	 after	 treatment.	No	 change	 in	
intraocular	 pressure	was	measured,	 during	 the	 follow-up	
period.	IOP	varied	between	14	and	19	mmHg.	Our	data	are	
summarized	in	Tables	1	and	2.
Discussion
PMD	has	been	postulated	to	the	abnormality	of	the	connective	
tissue,	but	the	exact	pathogenesis	is	still	unknown.	On	corneal	
topography,	marked	 steepening	 of	 the	 inferior	 corneal	
periphery	can	be	seen,	which	also	extends	into	mid-peripheral	
inferior	 corneal	meridians.	 The	mid-peripheral	 cornea	 is	
gradually	decreased	in	keratometric	power	above	the	inferior	
oblique	meridians.[3,6]	Our	patient	had	all	these	features	in	both	
eyes,	and	there	was	no	stromal	thickness	less	than	400	μm,	but	
the	left	eye	showed	less	deviation	than	the	right	eye.	The	usual	
treatments	for	PMD	are	intrastromal	ring	insertion,	lamellar	
keratoplasty,	 crescentic	 lamellar	 keratoplasty,	 penetrating	
keratoplasty,	cyanoacrylate	adhesive,	and	a	bandage	contact	
lens.	Conservative	treatment	is	also	possible.[7]
Corneal	 transplantation	 for	 keratectasia	 is	 a	 difficult	
procedure	with	a	 long	and	uncertain	visual	 recovery.	Ertan	
et al.[8]	 inserted	 intacs	 ring	 using	 a	 femtosecond	 laser	 to	
correct	 pellucid	marginal	 corneal	 degeneration	with	 safe	
and	efficient	results.	In	the	report	of	Stojanovic	et al.,	12	eyes	
were	 treated	with	 topography-guided	 custom	ablation	and	
CXL,	which	 after	uncorrected	visual	 acuity	 increased	 and	
astigmatism	and	keratometric	asymmetry	decreased.[9]	Spadea	
described	 eccentric	 irradiation	CXL	 technique	 followed	by	
us	in	case	of	PMD.[5]	Kymionis	et al.[10]	treated	a	woman	with	
simultaneous	photorefractive	keratectomy	and	corneal	CXL	
with	riboflavin-ultraviolet-A	irradiation	for	the	treatment	of	
progressive	pellucid	marginal	 corneal	degeneration	 in	both	
eyes	with	good	results.	Histologically	and	clinically,	CXL	 is	
a	well-circumscribed	and	well-published	therapic	possibility	
of	corneal	ectasias.[11,12]	There	are	some	possible	complications	
after	CXL:	early	pseudo-haze,	bacterial	infection,[13]	scarring,	
melting,	or	perforation.	The	 safety	parameter	of	 a	minimal	
stromal	thickness	of	400	μm	to	spare	the	endothelium.[14]
In	 this	 case,	 progression	 had	 been	 stopped	 by	 CXL	
treatment,	 and	 the	 best-corrected	 visual	 acuity	 increased	
during	 the	 observation	period.	No	 intraoperative	 or	 early	
postoperative	complications	occurred.	The	CXL	irradiation	was	
safe	and	efficient	in	the	treatment	of	certain	stages	of	PMDs 
with	the	help	of	which	progression	can	be	reversed	or	at	least	
stopped,	and	visual	acuity	can	be	improved.	This	method	may	
postpone	or	eliminate	the	need	of	corneal	transplantation	in	
cases	with	PMD.
Figure 1: Slit-lamp photograph of the right eye shows inferior 
steepening with a clear zone between limbus and the steep band
Table 1: Patient data before and after collage cross-linking treatment
Central corneal 
thickness (µm)
Peripheral corneal 
thickness (µm)
UCVA BCVA Intraocular 
pressure (mmHg)
Preoperative 505 520 +0.8 +0.7 14 
Postoperative 1 month 589 530 +0.6 +0.4 19
Postoperative 3 months 506 527 +0.55 +0.3 14 
Postoperative 6 months 501 518 +0.55 +0.3 16 
Postoperative 8 months 499 528 +0.3 +0.25 14 
UCVA: Uncorrected LogMAR visual acuity, BCVA: Best-corrected visual acuity
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Figure 3: Preoperative corneal topographic picture of the right eye 
shows the characteristic bow-tie appearance of corneal steepening 
(red zones) and midperipheral inferior corneal flattening
Figure 4: Corneal topograph shows flattening of the inferior cornea 
8 months after CXL treatment
Figure 5: Pre- and postoperative corneal back surface Scheimpflug 
pictures (Pentacam HR) do not show difference
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Figure 2: (a and b) Scheimpflug image (Oculus Pentacam HR) of the anterior segment shows irregular shaped central corneal region
ba
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
26	 Indian Journal of Ophthalmology	 Vol. ??? No. ???
degeneration.	J	Cataract	Refract	Surg	2006;32:1710-6.
9.	 Stojanovic	A,	Zhang	 J,	Chen	X,	Nitter	 TA,	Chen	 S,	Wang	Q.	
Topography-guided	transepithelial	surface	ablation	followed	by	
corneal	 collagen	 cross-linking	performed	 in	 a	 single	 combined	
procedure	for	the	treatment	of	keratoconus	and	pellucid	marginal	
degeneration.	J	Refract	Surg	2010;26:145-52.
10.	 Kymionis	 GD,	 Karavitaki	AE,	 Kounis	 GA,	 Portaliou	 DM,	
Yoo	SH,	Pallikaris	IG.	Management	of	pellucid	marginal	corneal	
degeneration	with	 simultaneous	 customized	 photorefractive	
keratectomy	and	 collagen	 crosslinking.	 J	Cataract	Refract	 Surg	
2009;35:1298-301.
11.	 Wollensak	G.	Crosslinking	treatment	of	progressive	keratoconus:	
New	hope.	Curr	Opin	Ophthalmol	2006;17:356-60.
12.	 Wollensak	G.	Corneal	collagen	cross-linking:	New	horizons.	Expert	
Rev	Ophthalmol	2010;5:201-15.
13.	 Sharma	N,	Maharana	P,	Singh	G,	Titiyal	JS.	Pseudomonas	keratitis	
after	collagen	crosslinking	for	keratoconus:	Case	report	and	review	
of	literature.	J	Cataract	Refract	Surg	2010;36:517-20.
14.	 Wollensak	G,	Spoerl	E,	Wilsch	M,	Seiler	T.	Endothelial	cell	damage	
after	 riboflavin-ultraviolet-A	 treatment	 in	 the	 rabbit.	 J	Cataract	
Refract	Surg	2003;29:1786-90.
Cite this article as: Citation will be included before issue gets online***
Source of Support: Nil. Conflict of Interest: None declared.
